MedTrace Logo

Efficacy and Safety of Biphasic Insulin Aspart 30 for the Treatment of Type 2 Diabetes Mellitus

NCT01542060 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 298

Last updated 2012-04-12

No results posted yet for this study

Summary

This study is conducted in Asia. The aim of this observational study is to collect efficacy and safety data of biphasic insulin aspart (NovoMix® 30) in type 2 diabetes under normal clinical practice conditions.

Conditions

Interventions

DRUG

biphasic insulin aspart 30

Administered via an insulin injection device. Dosages varied according to individual patients' medical requirement as determined by their attending clinician

Sponsors & Collaborators

Principal Investigators

  • Corporate Vice President for diabetes and devices · Novo Nordisk A/S

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2004-12-31
Completion
2004-12-31

Countries

  • Jordan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01542060 on ClinicalTrials.gov